CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders

January 13, 2017 updated by: Arkin

Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy

The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Attention Deficit Hyperactivity Disorder(ADHD) is an important comorbid condition in patients with substance use disorders (SUD). The prevalence of ADHD in patients with SUD is estimated 23%, and ADHD is associated with an untoward prognosis of SUD. However, adequate treatment programs for patients with ADHD and SUD are not available. Results of medication trials for patients with ADHD and SUD are disappointing, and cognitive behavioral therapy (CBT) has not yet been investigated in this population. In patients with ADHD without comorbid SUD, the results of CBT in randomized trials are positive. The purpose of this study is to investigate if CBT is effective in treating ADHD symptoms in patients with ADHD and SUD.

Study Type

Interventional

Enrollment (Actual)

184

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • substance use disorder
  • ADHD
  • able to comply with study activities

Exclusion Criteria:

  • severe neurological or psychiatric diseases (for example Parkinson, dementia, psychosis, bipolar depression) which require medication
  • unable to read or write Dutch language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: standard addiction treatment
10 sessions of standard addiction treatment. No ADHD treatment.
Experimental: addiction treatment and ADHD treatment
10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
Behavioral: cognitive behavioral therapy for treating ADHD symptoms
5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
self reported ADHD symptoms
Time Frame: 6 months
Dutch self report list of ADHD symptoms by Kooij and Buitelaar
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time Line Follow Back method
Time Frame: 6 months
self-reported alcohol and drug use
6 months
Beck depression inventory
Time Frame: 6 months
self reported depression symptoms
6 months
Beck Anxiety Inventory
Time Frame: 6 months
Self reported anxiety symptoms
6 months
EQ-5
Time Frame: 6 months
Self reported quality of living
6 months
TIC-P
Time Frame: 6 months
health care consumption and production loss in relation to mental health problems
6 months
Stroop task
Time Frame: 6 months
neuropsychological measure
6 months
Tower of London task
Time Frame: 6 months
neuropsychological task
6 months
BART task
Time Frame: 6 months
neuropsychological task on risk taking behavior
6 months
urine checks
Time Frame: 6 months
urine checks on drug use
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arkin

Collaborators

Fonds NutsOhra

Investigators

  • Principal Investigator: Robert Schoevers, MD, PhD, University Medical Center Groningen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

September 8, 2011

First Submitted That Met QC Criteria

September 8, 2011

First Posted (Estimate)

September 9, 2011

Study Record Updates

Last Update Posted (Estimate)

January 16, 2017

Last Update Submitted That Met QC Criteria

January 13, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 10-130

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Deficit Hyperactivity Disorder

Clinical Trials on cognitive behavioral therapy for treating ADHD symptoms

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe